ArticleCancer research2016
Ccl22 Diverts T Regulatory Cells and Controls the Growth of Melanoma.
Article in Cancer research, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 1 synthesis or guideline pooled it, 48 citations in OpenAlex.
- Engineered antigen-specific regulatory T cells for autoimmune skin conditions.Autoimmunity reviews · 2021Pooled it
- Regulatory T cells in cancer and inflammation.Signal transduction and targeted therapy · 2026Review
- Chemoradiation of glioblastoma cells alters expression of activation and immune checkpoint molecules on type 1 and 2 dendritic cells and impacts on subsequent T cell proliferation.Clinical and translational radiation oncology · 2026Article
- BAX as a Biomarker for Predicting Immunotherapeutic Efficacy in Uveal Melanoma Patients: A Comprehensive Analysis.Molecular biotechnology · 2026Article
- CAR-T cells in solid tumors: engineering, biomarkers, translational pathways and the road ahead.Frontiers in immunology · 2026Review
- Advancing CAR-based cell therapies for solid tumours: challenges, therapeutic strategies, and perspectives.Molecular cancer · 2025Review
- Article
- Reciprocal Modulation of Tumour and Immune Cell Motility: Uncovering Dynamic Interplays and Therapeutic Approaches.Cancers · 2025Review
- Natural killer cells are required for the recruitment of CD8+ T cells and the efficacy of immune checkpoint blockade in melanoma brain metastases.Journal for immunotherapy of cancer · 2024Article
- Chemokines and Cytokines in Immunotherapy of Melanoma and Other Tumors: From Biomarkers to Therapeutic Targets.International journal of molecular sciences · 2024Review
- Aflatoxin B1 and Epstein-Barr virus-induced CCL22 expression stimulates B cell infection.Proceedings of the National Academy of Sciences of the United States of America · 2024Article
- Downstream STING pathways IRF3 and NF-κB differentially regulate CCL22 in response to cytosolic dsDNA.Cancer gene therapy · 2024Article
- Skin Infiltrate Composition as a Telling Measure of Responses to Checkpoint Inhibitors.JID innovations : skin science from molecules to population health · 2023Article
- Macrophage-Derived Chemokine MDC/CCL22: An Ambiguous Finding in COVID-19.International journal of molecular sciences · 2023Article
- Human Regulatory T Cells: Understanding the Role of Tregs in Select Autoimmune Skin Diseases and Post-Transplant Nonmelanoma Skin Cancers.International journal of molecular sciences · 2023Review
- Targeting Epigenetic Mechanisms: A Boon for Cancer Immunotherapy.Biomedicines · 2023Review
- CRISPR/Cas9-mediated deletion of Interleukin-30 suppresses IGF1 and CXCL5 and boosts SOCS3 reducing prostate cancer growth and mortality.Journal of hematology & oncology · 2022Article
- Antimelanoma Effects of Concomitant Inhibition of SIRT1 and SIRT3 in BrafThe Journal of investigative dermatology · 2022Article
- Identification of the Crucial Role of CCL22 inFrontiers in genetics · 2022Article
- A Systematic Framework for Identifying Prognostic Genes in the Tumor Microenvironment of Colon Cancer.Frontiers in oncology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 2 institutions in 1 country.
Funding
Abstract
T regulatory cells (Treg) avert autoimmunity, but their increased levels in melanoma confer a poor prognosis. To explore the basis for Treg accumulation in melanoma, we evaluated chemokine expression in patients. A 5-fold increase was documented in the Treg chemoattractants CCL22 and CCL1 in melanoma-affected skin versus unaffected skin, as accompanied by infiltrating FoxP3
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.